Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Inclusion Criteria:

- Histologically confirmed SCCHN from any of the following primary sites: oral cavity,
oropharynx, hypopharynx, and larynx.

- Must have recurrent or metastatic disease that is not amenable to therapy with
curative intent (surgery and/or radiation therapy with or without chemotherapy).

- No prior treatment with systemic anti-cancer therapy for SCCHN unless protocol-defined
conditions are met.

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to1.

- Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per
RECIST v1.1.

- Documentation of program death ligand-1 (PD-L1) status prior to randomization.

Exclusion Criteria:

- Recurrent or metastatic carcinoma of the nasopharynx and paranasal sinuses, squamous
cell carcinoma that originated from the skin and salivary gland or non-squamous
histologies (e.g., mucosal melanoma) and SCCHN of unknown primary origin.

- Untreated central nervous system (CNS) metastases.

- Carcinomatous meningitis.

- Active, known or suspected autoimmune disease.

- Physical and laboratory test findings outside the protocol-defined range.